N D Sabin1, Y T Cheung2, W E Reddick3, D Bhojwani4, W Liu5, J O Glass3, T M Brinkman2,6, S N Hwang3, D Srivastava5, C-H Pui7, L L Robison2, M M Hudson2,7, K R Krull2,6. 1. From the Departments of Diagnostic Imaging (N.D.S., W.E.R., J.O.G., S.N.H.) noah.sabin@stjude.org. 2. Epidemiology and Cancer Control (Y.T.C., T.M.B., L.L.R., M.M.H., K.R.K.). 3. From the Departments of Diagnostic Imaging (N.D.S., W.E.R., J.O.G., S.N.H.). 4. Children's Center for Cancer and Blood Diseases (D.B.), Children's Hospital Los Angeles, Los Angeles, California. 5. Biostatistics (W.L., D.S.). 6. Psychology (T.M.B., K.R.K.). 7. Oncology (C.-H.P., M.M.H.), St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
BACKGROUND AND PURPOSE: Survivors of acute lymphoblastic leukemia are at risk for neurocognitive deficits and leukoencephalopathy. We performed a longitudinal assessment of leukoencephalopathy and its associations with long-term brain microstructural white matter integrity and neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a modern chemotherapy-only protocol. MATERIALS AND METHODS: One hundred seventy-three survivors of acute lymphoblastic leukemia (49% female), treated on a chemotherapy-only protocol, underwent brain MR imaging during active therapy and repeat imaging and neurocognitive testing at follow-up (median, 13.5 years of age; interquartile range, 10.7-17.6 years; median time since diagnosis, 7.5 years; interquartile range, 6.3-9.1 years). Persistence of leukoencephalopathy was examined in relation to demographic and treatment data and to brain DTI in major fiber tracts and neurocognitive testing at follow-up. RESULTS: Leukoencephalopathy was found in 52 of 173 long-term survivors (30.0%) and persisted in 41 of 52 (78.8%) who developed it during therapy. DTI parameters were associated with leukoencephalopathy in multiple brain regions, including the corona radiata (fractional anisotropy, P = .001; mean diffusivity, P < .001), superior longitudinal fasciculi (fractional anisotropy, P = .02; mean diffusivity, P < .001), and superior fronto-occipital fasciculi (fractional anisotropy, P = .006; mean diffusivity, P < .001). Mean diffusivity was associated with neurocognitive impairment including in the genu of the corpus callosum (P = .04), corona radiata (P = .02), and superior fronto-occipital fasciculi (P = .02). CONCLUSIONS: Leukoencephalopathy during active therapy and neurocognitive impairment at long-term follow-up are associated with microstructural white matter integrity. DTI may be more sensitive than standard MR imaging for detection of clinically consequential white matter abnormalities in childhood acute lymphoblastic leukemia survivors treated with chemotherapy and in children undergoing treatment.
BACKGROUND AND PURPOSE: Survivors of acute lymphoblastic leukemia are at risk for neurocognitive deficits and leukoencephalopathy. We performed a longitudinal assessment of leukoencephalopathy and its associations with long-term brain microstructural white matter integrity and neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a modern chemotherapy-only protocol. MATERIALS AND METHODS: One hundred seventy-three survivors of acute lymphoblastic leukemia (49% female), treated on a chemotherapy-only protocol, underwent brain MR imaging during active therapy and repeat imaging and neurocognitive testing at follow-up (median, 13.5 years of age; interquartile range, 10.7-17.6 years; median time since diagnosis, 7.5 years; interquartile range, 6.3-9.1 years). Persistence of leukoencephalopathy was examined in relation to demographic and treatment data and to brain DTI in major fiber tracts and neurocognitive testing at follow-up. RESULTS:Leukoencephalopathy was found in 52 of 173 long-term survivors (30.0%) and persisted in 41 of 52 (78.8%) who developed it during therapy. DTI parameters were associated with leukoencephalopathy in multiple brain regions, including the corona radiata (fractional anisotropy, P = .001; mean diffusivity, P < .001), superior longitudinal fasciculi (fractional anisotropy, P = .02; mean diffusivity, P < .001), and superior fronto-occipital fasciculi (fractional anisotropy, P = .006; mean diffusivity, P < .001). Mean diffusivity was associated with neurocognitive impairment including in the genu of the corpus callosum (P = .04), corona radiata (P = .02), and superior fronto-occipital fasciculi (P = .02). CONCLUSIONS:Leukoencephalopathy during active therapy and neurocognitive impairment at long-term follow-up are associated with microstructural white matter integrity. DTI may be more sensitive than standard MR imaging for detection of clinically consequential white matter abnormalities in childhood acute lymphoblastic leukemia survivors treated with chemotherapy and in children undergoing treatment.
Authors: Michelle N Edelmann; Kevin R Krull; Wei Liu; John O Glass; Qing Ji; Robert J Ogg; Noah D Sabin; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Wilburn E Reddick Journal: Brain Date: 2014-08-13 Impact factor: 13.501
Authors: Michael J Fisher; Zarir P Khademian; Erin M Simon; Robert A Zimmerman; Larissa T Bilaniuk Journal: AJNR Am J Neuroradiol Date: 2005-08 Impact factor: 3.825
Authors: Wilburn E Reddick; John O Glass; Kathleen J Helton; James W Langston; Xiaoping Xiong; Shengjie Wu; Ching-Hon Pui Journal: AJNR Am J Neuroradiol Date: 2005-05 Impact factor: 3.825
Authors: Ilse Schuitema; Sabine Deprez; Wim Van Hecke; Marita Daams; Anne Uyttebroeck; Stefan Sunaert; Frederik Barkhof; Eline van Dulmen-den Broeder; Helena J van der Pal; Cor van den Bos; Anjo J P Veerman; Leo M J de Sonneville Journal: J Clin Oncol Date: 2013-08-19 Impact factor: 44.544
Authors: Kevin R Krull; Yin Ting Cheung; Wei Liu; Slim Fellah; Wilburn E Reddick; Tara M Brinkman; Cara Kimberg; Robert Ogg; Deokumar Srivastava; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544
Authors: Ching-Hon Pui; Dario Campana; Deqing Pei; W Paul Bowman; John T Sandlund; Sue C Kaste; Raul C Ribeiro; Jeffrey E Rubnitz; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; Larry E Kun; Sima Jeha; Cheng Cheng; Scott C Howard; Vickey Simmons; Amy Bayles; Monika L Metzger; James M Boyett; Wing Leung; Rupert Handgretinger; James R Downing; William E Evans; Mary V Relling Journal: N Engl J Med Date: 2009-06-25 Impact factor: 91.245
Authors: Marina Genschaft; Thomas Huebner; Franziska Plessow; Vasiliki N Ikonomidou; Nasreddin Abolmaali; Franziska Krone; Andre Hoffmann; Elisabeth Holfeld; Peter Vorwerk; Christof Kramm; Bernd Gruhn; Elisabeth Koustenis; Pablo Hernaiz-Driever; Rakesh Mandal; Meinolf Suttorp; Thomas Hummel; Chrysanthy Ikonomidou; Clemens Kirschbaum; Michael N Smolka Journal: PLoS One Date: 2013-11-12 Impact factor: 3.240
Authors: Shelli R Kesler; Charlotte Sleurs; Brenna C McDonald; Sabine Deprez; Ellen van der Plas; Brian J Nieman Journal: J Clin Oncol Date: 2021-04-22 Impact factor: 50.717
Authors: Liwen Peng; Lok Sum Yang; Perri Yam; Chun Sing Lam; Agnes Sui-Yin Chan; Chi Kong Li; Yin Ting Cheung Journal: Front Oncol Date: 2021-04-20 Impact factor: 6.244
Authors: Mustapha Bouhrara; Nikkita Khattar; Palchamy Elango; Susan M Resnick; Luigi Ferrucci; Richard G Spencer Journal: Int J Obes (Lond) Date: 2021-01-22 Impact factor: 5.551